Evidence map›Paper›PMID 40369846›Full record

ArticleExperimental dermatology2025

Memory T-Cell Phenotype in Cutaneous T-Cell Lymphoma Is Modified by Germline Gene Gametocyte Specific Factor 1.

Amelia Martínez Villarreal, Jennifer Gantchev, Pingxing Xie, Philippe Lefrançois, Brandon Ramchatesingh, Ivan V Litvinov

Abstract read
In one paragraph

Article in Experimental dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amelia Martínez VillarrealFaculty of Medicine and Health Sciences, Research Institute of the McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
Jennifer GantchevDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Pingxing XieDivision of Dermatology, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
Philippe LefrançoisDivision of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
Brandon RamchatesinghFaculty of Medicine and Health Sciences, Research Institute of the McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
Ivan V LitvinovFaculty of Medicine and Health Sciences, Research Institute of the McGill University Health Centre, McGill University, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0001-7422-307X

Funding

Cancer Research SocietyCIHRConsejo Nacional de Ciencia y TecnologíaFonds de Recherche du Québec - Santé
6 · The paper itself

Abstract

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of lymphoproliferative disorders characterised by skin infiltration by malignant memory T cells. While most patients will present with an indolent disease, others will follow a highly aggressive clinical course. Currently, defining disease prognosis remains challenging. Ectopic expression of gametocyte-specific factor 1 (GTSF1) has emerged as a potential prognostic biomarker. However, its contribution to CTCL carcinogenesis remains unknown. Here, we report that GTSF1 contributes to carcinogenesis by partially modifying the memory/effector phenotype of the malignant T cells. GTSF1 knockdown in CTCL cells led to T-cell activation and production of IFNγ and TNFα. Advanced stages of the disease are associated with decreased production of these cytokines. Notably, we show that patients classified with high expression of GTSF1 are associated with a worse disease prognosis. Taken together, our findings indicate that GTSF1 expression in CTCL cells allows them to acquire memory T-cell phenotype. Malignant memory T cells have a decreased production of immune-responsive cytokines, leading to a diminished immune response and disease progression. GTSF1 is an important candidate as a prognostic biomarker. Furthermore, understanding the specific function of GTSF1 might help develop novel targeted treatment options for CTCL patients.

Indexed as

Lymphoma, T-Cell, CutaneousMemory T CellsSkin NeoplasmsCell Line, TumorFemaleHumansImmunologic MemoryInterferon-gammaLymphocyte ActivationMaleMiddle AgedPhenotypePrognosisTumor Necrosis Factor-alphaInterferon-gammaTumor Necrosis Factor-alphacutaneous T‐cell lymphoma (CTCL)gametocyte specific factor 1 (GTSF1)prognostic biomarkerretrotansposonsTh2

Identifiers

PMID40369846
PMCPMC12078864

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.